These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 29409576)

  • 61. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.
    Roberts AW; Carpenter DM; Smith A; Look KA
    Res Social Adm Pharm; 2019 Feb; 15(2):222-225. PubMed ID: 29650444
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evidence-Based Guidelines for EMS Administration of Naloxone.
    Williams K; Lang ES; Panchal AR; Gasper JJ; Taillac P; Gouda J; Lyng JW; Goodloe JM; Hedges M
    Prehosp Emerg Care; 2019; 23(6):749-763. PubMed ID: 30924736
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Naloxone Administration Frequency During Emergency Medical Service Events - United States, 2012-2016.
    Cash RE; Kinsman J; Crowe RP; Rivard MK; Faul M; Panchal AR
    MMWR Morb Mortal Wkly Rep; 2018 Aug; 67(31):850-853. PubMed ID: 30091966
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users.
    Acharya M; Chopra D; Hayes CJ; Teeter B; Martin BC
    Value Health; 2020 Apr; 23(4):451-460. PubMed ID: 32327162
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3: Is nebulised naloxone effective in opioid overdose?
    Ishiyama D; Jones J
    Emerg Med J; 2013 Oct; 30(10):860. PubMed ID: 24014692
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems.
    Elzey MJ; Fudin J; Edwards ES
    Expert Opin Drug Deliv; 2017 Sep; 14(9):1045-1058. PubMed ID: 27606669
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality.
    Kim D; Irwin KS; Khoshnood K
    Am J Public Health; 2009 Mar; 99(3):402-7. PubMed ID: 19150908
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Implementation of a Pharmacist-Led, Multidisciplinary Naloxone Patient Education Program at an Academic Medical Center.
    Sze J; Chan T; Dalpoas S; Kiruthi C; Harris CM; Gundareddy V; Parker MS; Jacob E
    J Pharm Pract; 2023 Oct; 36(5):1201-1210. PubMed ID: 35484711
    [No Abstract]   [Full Text] [Related]  

  • 69. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
    Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
    Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.
    Green TC; Case P; Fiske H; Baird J; Cabral S; Burstein D; Schwartz V; Potter N; Walley AY; Bratberg J
    J Am Pharm Assoc (2003); 2017; 57(2S):S19-S27.e4. PubMed ID: 28214219
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Telephone-based opioid overdose education and naloxone distribution (OEND) pharmacy consult clinic.
    Szydlowski EM; Caruana SS
    Subst Abus; 2018; 39(2):145-151. PubMed ID: 31032747
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Emergency medical services naloxone access: a national systematic legal review.
    Davis CS; Southwell JK; Niehaus VR; Walley AY; Dailey MW
    Acad Emerg Med; 2014 Oct; 21(10):1173-7. PubMed ID: 25308142
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Engaging Law Enforcement in Overdose Reversal Initiatives: Authorization and Liability for Naloxone Administration.
    Davis CS; Carr D; Southwell JK; Beletsky L
    Am J Public Health; 2015 Aug; 105(8):1530-7. PubMed ID: 26066921
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Naloxone auto-injector gains FDA approval.
    Knopf A
    Behav Healthc; 2014; 34(3):48-9. PubMed ID: 25065155
    [No Abstract]   [Full Text] [Related]  

  • 75. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
    Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
    Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Police Officers Can Safely and Effectively Administer Intranasal Naloxone.
    Fisher R; O'Donnell D; Ray B; Rusyniak D
    Prehosp Emerg Care; 2016; 20(6):675-680. PubMed ID: 27218446
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Naloxone (Narcan) nasal spray for opioid overdose.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):1-2. PubMed ID: 26714239
    [No Abstract]   [Full Text] [Related]  

  • 78. Factors associated with naloxone administration in an opioid dependent sample.
    Kenney SR; Anderson BJ; Bailey GL; Stein MD
    J Subst Abuse Treat; 2018 Jan; 84():17-20. PubMed ID: 29195589
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Associations between naloxone prescribing and opioid overdose among patients with acute and chronic pain conditions.
    Qeadan F; Madden EF
    Addiction; 2022 Feb; 117(2):457-471. PubMed ID: 34286895
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders.
    Bach P; Hartung D
    Addict Sci Clin Pract; 2019 Sep; 14(1):30. PubMed ID: 31474225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.